Randomized trial · people
Tirzepatide: 62% MASH resolution in 15 mg arm vs 10% on placebo
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In people with MASH and moderate or severe fibrosis, 52 weeks of tirzepatide led to MASH resolution without worse fibrosis more often than placebo in this phase 2 trial.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 190
- Published
- 2024
- Journal
- N Engl J Med
What they tested
The team tested whether once-weekly tirzepatide could resolve MASH, a progressive liver disease, without worsening fibrosis (scarring) in people with moderate or severe fibrosis.
How the study was done
A phase 2, double-blind, randomized, placebo-controlled trial at many centers in 190 participants with biopsy-confirmed MASH and stage F2 or F3 fibrosis. Each person got a weekly shot of tirzepatide (5 mg, 10 mg or 15 mg arm) or placebo, a dummy shot, for 52 weeks.

Model. Individual results vary.
What they found
At 52 weeks, MASH resolved without worse fibrosis in 10% on placebo, 44% in the 5 mg arm, 56% in the 10 mg arm and 62% in the 15 mg arm (P<0.001 for each). Fibrosis improved by at least one stage without worse MASH in 30% on placebo, 55% in the 5 mg arm and 51% in both the 10 mg and 15 mg arms. The most common side effects with tirzepatide were gut-related, and most were mild or moderate.
What it doesn’t show
This was a 52-week phase 2 trial, and only 157 of the 190 people had a week 52 liver biopsy that could be scored, so missing results were filled in using the placebo group's pattern. It was funded by Eli Lilly, and the authors say larger and longer trials are needed.
The paper
Loomba et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. N Engl J Med. 2024.
The compound
More studies on Tirzepatide
- Tirzepatide plus apitegromab: 1.9 kg less lean mass loss in EMBRAZERandomized trial · people · 2026
- Dulaglutide: switching to tirzepatide beat dose escalation on HbA1cRandomized trial · people · 2025
- Tirzepatide: up to 19.7% weight loss at 176 weeks in SURMOUNT-1Randomized trial · people · 2025
- Tirzepatide: about 75% of weight lost was fat in SURMOUNT-1Randomized trial · people · 2025
- Tirzepatide: most reached a weight plateau by week 72 in SURMOUNT-1Randomized trial · people · 2025
- Tirzepatide: 20.2% weight loss vs 13.7% on semaglutide at 72 weeksRandomized trial · people · 2025
- Every study on Tirzepatide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.